Advertisement

June 13, 2019

QXMédical Licenses Bioresorbable Embolic Technology From University of Minnesota

June 10, 2019—QXMédical announced that it has acquired the worldwide exclusive rights to the bioresorbable embolic technology developed at the University of Minnesota for resorbable and drug-loadable microspheres and hydrogels to be marketed to interventional radiologists and oncologists to occlude vessels for a variety of clinical indications. QXMédical will bring this next-generation technology through regulatory approval and commercialization.

According to the company, the embolic agents developed by the University of Minnesota scientists can be absorbed by the body after the therapeutic treatment has been obtained. Made of organic materials, these agents degrade at a controlled rate and are eventually reabsorbed by the body. They do not permanently occlude blood vessels supplying healthy tissue and may allow for better restoration of artery integrity after embolization compared with permanent microspheres and gels. Additionally, these organic materials have the potential to load different drugs, including chemotherapeutic agents, for transarterial chemoembolization procedures.

As outlined by QXMédical, benefits for this therapy include:

  • Arterial embolization to treat trauma, bleeding, hypervascular tumors, arterial venous malformations. prostate artery embolization, uterine fibroid embolization, and some types of cancer.
  • Minimizes inflammatory response and allows for future vascular access after the therapeutic benefit of embolization has been achieved.
  • Minimizes the effect of nontargeted delivery of microspheres and gels which can be problematic with permanent embolics.
  • Ability to be loaded with various drugs (including chemotherapy agents) to allow targeted delivery while decreasing overall systemic exposure.

Jafar Golzarian, MD, is an inventor of the resorbable embolic technology as well as Director of Interventional Radiology & Vascular Imaging at the University of Minnesota in Minneapolis, Minnesota. In the company's announcement, Dr. Golzarian commented, "There is an increasing demand by patients and physicians for inert, easy-to-use, loadable, and resorbable materials. After the clinical result is obtained, the foreign material is removed from the body, reducing the risk of chronic inflammation and continuous drug release. Restoration of the nontarget vessels is a potential added benefit of this technology."

Advertisement


June 17, 2019

Merit Medical Acquires Brightwater Medical

June 13, 2019

Orchestra BioMed Partners With Terumo to Develop and Commercialize the Virtue Sirolimus-Eluting Balloon